India pharmaceutical company Cadila Healthcare announced on Thursday that it was launching a generic version of antiviral drug remdesivir, which is being used for treating serious cases of COVID-19 at a more competitive price for the Indian market.
The medication, which will be sold under the brand name Remdac, will be priced at around 2,800 rupees ($36) for a 100 mg injection, the company said in a statement.
Source: efe.com , English edition
Комментариев нет:
Отправить комментарий